Evogene Ltd. (TLV:EVGN)

Market Cap	25.42M -25.3%
Revenue (ttm)	12.28M -30.9%
Net Income	-27.05M
EPS	-3.44
Shares Out	9.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,618
Average Volume	37,580
Open	258.60
Previous Close	249.90
Day's Range	253.30 - 259.00
52-Week Range	231.20 - 1,085.00
Beta	0.95
RSI	44.59
Earnings Date	May 20, 2026

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: EVGN

Financial Performance

In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.

Financial numbers in USD